SBRA
Sabra Healthcare REIT Inc
19.20$
-0.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 31.6% | 31.7% | 24.7% | 2.1% | 1.1% | 2.2% | 4.4% | 7.9% | 16.4% | 22.0% | 24.8% | 26.0% | 30.2% | 32.3% | 35.0% | |
| 100.0% | 100.0% | 100.0% | 100.0% | 97.9% | 98.9% | 97.8% | 95.6% | 92.1% | 83.6% | 78.0% | 75.2% | 74.0% | 69.8% | 67.7% | 65.0% | |
| – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | |
| 18.2% | 17.2% | 15.6% | 12.2% | 16.0% | 10.0% | 7.6% | 8.0% | 5.8% | 4.6% | 5.5% | 6.1% | 6.3% | 7.3% | 7.1% | 6.9% | |
| 96.6% | 48.8% | 44.9% | 36.9% | 39.6% | 41.8% | 36.1% | 40.3% | 42.8% | 4.6% | 78.0% | 38.2% | 36.4% | 35.6% | 31.2% | 30.9% | |
| 2.3% | 51.2% | 55.1% | 63.1% | 60.4% | 57.1% | 61.8% | 55.3% | 49.2% | 79.0% | 40.3% | 37.0% | 37.6% | 34.2% | 36.5% | 34.1% | |
| 0.0% | 36.0% | 35.9% | 30.0% | 25.6% | 24.8% | 24.9% | 21.8% | 23.6% | 18.9% | 16.8% | 17.3% | 16.9% | 17.4% | 16.4% | 14.5% | |
| 2.3% | 15.2% | 18.9% | 25.0% | 25.6% | 33.2% | 26.9% | 39.2% | 45.3% | 10.8% | 23.2% | -19.6% | -12.2% | 2.4% | 18.2% | 20.3% | |
| 2.8% | 0.0% | 38.0% | 29.4% | 26.4% | 25.7% | 29.0% | 0.2% | 0.5% | 0.5% | 0.1% | 0.3% | 0.2% | 0.3% | 0.1% | 0.2% | |
| 83.8% | 15.2% | 18.9% | 25.0% | 25.6% | 33.2% | 27.0% | 39.0% | 44.8% | 10.3% | 23.1% | -19.9% | -12.4% | 2.1% | 18.0% | 20.1% | |
| 82.3% | 31.6% | 29.3% | 24.7% | 105.5% | 116.3% | 109.5% | 87.3% | 82.1% | 78.9% | 69.5% | 29.2% | 34.7% | 48.2% | 58.7% | 59.0% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.